A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2015
At a glance
- Drugs Ibutamoren (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 30 Jan 2009 Planned patient numbers (512) added as reported by ClinicalTrials.gov.
- 30 Jan 2009 Trial phase changed from II/III to II as reported by ClinicalTrials.gov.
- 30 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.